Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Mol – page 77

1 758 clinical trials in Mol, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mol at a glance
1 758
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 758 trials in Mol

Open in trial search

Crohn's disease

Not recruiting

Study on Tulisokibart for Treating Moderate to Severe Crohn's Disease in Adults

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Active Axial Spondyloarthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

A Study Testing VX-407 in Patients with Autosomal Dominant Polycystic Kidney Disease Who Have Specific PKD1 Gene Changes

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:VX-407
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on the Safety and Effectiveness of a UTI Vaccine (GSKVX000000046019) for Adults Aged 18-64 and Women Aged 18-64 with Urinary Tract Infections

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:GSKVX000000044501
  • Sponsor:GlaxoSmithKline Biologicals

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of inhaled alpha1-proteinase inhibitor (Kamada-AAT) in adults with alpha-1 antitrypsin deficiency and moderate to severe airflow limitation

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALPHA-1-ANTITRYPSIN
  • Sponsor:Kamada Ltd.

B-cell lymphoma+1

Not recruiting

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Study on Luspatercept for Patients with Lower-risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Pulmonary sarcoidosis

Not recruiting

Study on the Effects and Safety of Namilumab for Patients with Chronic Lung Sarcoidosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Namilumab
  • Sponsor:Kinevant Sciences GmbH

Study of Imetelstat in Patients with Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Refractory to Erythropoiesis-Stimulating Agents

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imetelstat Sodium
  • Sponsor:Geron Corp.

Study on Long-Term Safety of Secukinumab for Patients with Polymyalgia Rheumatica

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Mol

What the registry says about research in the country

01 Cardiovascular Research

Clinical trials focusing on cardiovascular conditions, specifically examining new therapeutic approaches for heart-related disorders.

  • Atrial Fibrillation Studies
  • Acute Coronary Syndrome Research
  • Stroke Prevention Initiatives

These studies evaluate novel treatments targeting cardioembolic events and investigating approaches to reduce recurrent cardiovascular events in patients with various heart conditions.

02 Cardiac Therapeutics

Research centered on developing and testing new cardiovascular medications for improving patient outcomes in heart-related conditions.

  • Heart Attack Prevention
  • Systemic Embolism Prevention
  • Cardiovascular Risk Management

The studies aim to evaluate therapeutic effectiveness in reducing major adverse cardiac events and improving long-term patient outcomes.

03 Preventive Cardiology

Clinical research focusing on preventive measures for cardiac complications and stroke in high-risk patients.

  • Post-Heart Attack Care
  • Stroke Risk Reduction
  • Cardiac Event Prevention

These trials examine innovative approaches to prevent recurring cardiovascular events and improve standard-of-care treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.